Abstract
BackgroundThe development of antibody-based therapeutics for the neurological diseases and glioma is largely hampered due to the blood-brain barrier (BBB). It is appealing to identify more promising targets that are...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
